跳至主要内容
临床试验/RPCEC00000274
RPCEC00000274招募中1 期

Evaluation of the intra-lesional application of a inductive bioactive formulation for the treatment of cysts and tumors of the facial mass: Clinical Trial Phase I-ll - TXMAXILAR

aval Hospital of Acapulco of the Mexican Navy0 个研究点目标入组 30 人开始时间: 2018年5月30日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment

入排标准

年龄范围
9 years 至 one(—)
性别
All

入选标准

  • 1. Volunteer patients over 18 years of age who sign informed consent.
  • 2. Patients between 9 and 17 years old, who agree to receive treatment and whose parents or guardians authorize and sign an informed consent (both parents or guardians).
  • 3. Patients with clinical, radiographic and histopathological diagnosis of any of the following pathologies of benign histology: dentigerous cysts, odontogenic keratocystic tumors, ameloblastomas, ossifying fibroblasts, fibrous dysplasia, Gorham-Stout syndrome, other benign histology lesions of the jaws selected at the discretion of the specialist.
  • 4. Patients with diseases described in previous point and with recurrence to previous treatments.

排除标准

  • 1. Rheumatoid arthritis.
  • 2. Autoimmune diseases.
  • 3. Decompensated systemic disease .
  • 4. Creatinine 1.25 times the normal value or creatinine clearance less than 50 milliliters / minute (Cockfrot and Gault method).
  • 5. Blood leucocytes less than 3000 cells / microliter or platelet count less than 100,000 / microliter.
  • 6. Blood hemoglobin less than 10 g / deciliter.
  • 7. Increase in the last month of diastolic blood pressure to 110 mmHg or more.
  • 8. Hematuria or proteinuria greater than 300 milligrams/day.
  • 9. Women who are lactating, pregnant or of childbearing age and sexually active without contraception: salpingoclasm, intrauterine device or hormonal contraceptives. This condition must be maintained for at least 6 months after the last application of the inductive bioactive formulation.
  • 10. Alcoholism and/or drug addiction.
  • 11. Known liver disease with twice the increase in liver function tests (Aspartate aminotransferase (AST), Alaninoamino transferase (ALT), alkaline phosphatase, bilirubin).
  • 12. Presence of Cancer.
  • 13. Other pathologies at the discretion of the investigator.

研究者

发起方
aval Hospital of Acapulco of the Mexican Navy

相似试验